These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 15294425)

  • 1. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2004 Sep; 66(5):1259-83. PubMed ID: 15294425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2005 Jul; 67(4):783-813. PubMed ID: 15893553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Explicitly accounting for antiretroviral drug uptake in theoretical HIV models predicts long-term failure of protease-only therapy.
    Smith RJ
    J Theor Biol; 2008 Mar; 251(2):227-37. PubMed ID: 18191950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiretroviral therapy and immune reconstitution].
    Carcelain G; Li TS; Renaud M; Blanc C; Tubiana R; Calvez V; Leibowitch J; Debré P; Agut H; Katlama C; Autran B
    J Soc Biol; 1999; 193(1):5-10. PubMed ID: 10851549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nature of equilibria and effects of drug treatments in some simple viral population dynamical models.
    Tuckwell HC; Wan FY
    IMA J Math Appl Med Biol; 2000 Dec; 17(4):311-27. PubMed ID: 11270747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads.
    Wein LM; D'Amato RM; Perelson AS
    J Theor Biol; 1998 May; 192(1):81-98. PubMed ID: 9628841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7.
    Beq S; Bugault F; Colle JH; Lambotte O; Delfraissy JF; Thèze J
    Eur Cytokine Netw; 2005 Dec; 16(4):293-9. PubMed ID: 16464744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
    Shi V; Tridane A; Kuang Y
    J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
    Canestri A; Ghosn J; Wirden M; Marguet F; Ktorza N; Boubezari I; Dominguez S; Bossi P; Caumes E; Calvez V; Katlama C
    Antivir Ther; 2006; 11(5):561-6. PubMed ID: 16964823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The problem with antivirals alone.
    TreatmentUpdate; 1999 Mar; 11(2):1-2. PubMed ID: 11366774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global stability of an HIV-1 model with distributed intracellular delays and a combination therapy.
    Liu S; Wang L
    Math Biosci Eng; 2010 Jul; 7(3):675-85. PubMed ID: 20578792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic multidrug therapies for HIV: a control theoretic approach.
    Wein LM; Zenios SA; Nowak MA
    J Theor Biol; 1997 Mar; 185(1):15-29. PubMed ID: 9093552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HIV-1 quantitative dynamics in vivo: a review of mathematical models].
    Le Corfec E; Rouzioux C; Costagliola D
    Rev Epidemiol Sante Publique; 2000 Apr; 48(2):168-81. PubMed ID: 10804426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
    Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
    Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.